Companies House 12709586 2025-07-31 2025-07-31 2024-08-01 false iso4217:GBP xbrli:pure 12709586 2023-08-01 2024-07-31 12709586 2025-07-31 12709586 2024-08-01 2025-07-31 12709586 2024-07-31 12709586 curr:PoundSterling 2024-08-01 2025-07-31 12709586 uk-bus:CompanyLimitedByGuarantee 2024-08-01 2025-07-31 12709586 uk-bus:FRS102 2024-08-01 2025-07-31 12709586 uk-bus:AuditExempt-NoAccountantsReport 2024-08-01 2025-07-31 12709586 uk-bus:FullAccounts 2024-08-01 2025-07-31 12709586 uk-bus:RegisteredOffice 2024-08-01 2025-07-31 12709586 uk-bus:Director1 2024-08-01 2025-07-31 12709586 uk-bus:Director2 2024-08-01 2025-07-31 12709586 uk-bus:Director3 2024-08-01 2025-07-31 12709586 uk-bus:Director4 2024-08-01 2025-07-31 12709586 uk-bus:Director5 2024-08-01 2025-07-31 12709586 uk-bus:Director6 2024-08-01 2025-07-31 12709586 uk-bus:Director7 2024-08-01 2025-07-31 12709586 uk-bus:Director8 2024-08-01 2025-07-31 12709586 uk-bus:Director9 2024-08-01 2025-07-31 12709586 uk-bus:Director10 2024-08-01 2025-07-31 12709586 uk-bus:Director11 2024-08-01 2025-07-31 12709586 uk-bus:Director12 2024-08-01 2025-07-31 12709586 uk-bus:Director13 2024-08-01 2025-07-31 12709586 uk-bus:Director14 2024-08-01 2025-07-31 12709586 uk-bus:Director15 2024-08-01 2025-07-31 12709586 uk-bus:Director16 2024-08-01 2025-07-31 12709586 uk-bus:Director17 2024-08-01 2025-07-31 12709586 uk-bus:Director18 2024-08-01 2025-07-31 12709586 uk-bus:Director19 2024-08-01 2025-07-31 12709586 uk-bus:Director20 2024-08-01 2025-07-31 12709586 uk-bus:Director21 2024-08-01 2025-07-31 12709586 uk-bus:CompanySecretary1 2024-08-01 2025-07-31 12709586 core:AfterOneYear 2025-07-31 12709586 core:AfterOneYear 2024-07-31 12709586 core:WithinOneYear 2025-07-31 12709586 core:WithinOneYear 2024-07-31 12709586 core:WithinOneYear 2024-08-01 2025-07-31 12709586 core:AfterOneYear 2025-07-31 12709586 core:AfterOneYear 2024-07-31 12709586 core:AfterOneYear 2024-08-01 2025-07-31 12709586 core:ShareCapital 2025-07-31 12709586 core:ShareCapital 2024-07-31 12709586 core:SharePremium 2025-07-31 12709586 core:SharePremium 2024-07-31 12709586 core:OtherReservesSubtotal 2025-07-31 12709586 core:OtherReservesSubtotal 2024-07-31 12709586 core:RevaluationReserve 2025-07-31 12709586 core:RevaluationReserve 2024-07-31 12709586 core:RetainedEarningsAccumulatedLosses 2025-07-31 12709586 core:RetainedEarningsAccumulatedLosses 2024-07-31 12709586 1 2024-08-01 2025-07-31 12709586 2 2024-08-01 2025-07-31 12709586 3 2024-08-01 2025-07-31 12709586 core:LandBuildings 2024-08-01 2025-07-31 12709586 core:LandBuildings 2025-07-31 12709586 core:LandBuildings 2023-08-01 2024-07-31 12709586 core:LandBuildings 2024-07-31 12709586 core:PlantMachinery 2024-08-01 2025-07-31 12709586 core:PlantMachinery 2025-07-31 12709586 core:PlantMachinery 2023-08-01 2024-07-31 12709586 core:PlantMachinery 2024-07-31 12709586 core:FurnitureFittingsToolsEquipment 2024-08-01 2025-07-31 12709586 core:FurnitureFittingsToolsEquipment 2025-07-31 12709586 core:FurnitureFittingsToolsEquipment 2023-08-01 2024-07-31 12709586 core:FurnitureFittingsToolsEquipment 2024-07-31 12709586 core:OfficeEquipment 2024-08-01 2025-07-31 12709586 core:OfficeEquipment 2025-07-31 12709586 core:OfficeEquipment 2023-08-01 2024-07-31 12709586 core:OfficeEquipment 2024-07-31 12709586 core:Vehicles 2024-08-01 2025-07-31 12709586 core:Vehicles 2025-07-31 12709586 core:Vehicles 2023-08-01 2024-07-31 12709586 core:Vehicles 2024-07-31 12709586 core:NetGoodwill 2024-08-01 2025-07-31 12709586 core:NetGoodwill 2025-07-31 12709586 core:NetGoodwill 2023-08-01 2024-07-31 12709586 core:NetGoodwill 2024-07-31 12709586 core:IntangibleAssetsOtherThanGoodwill 2024-08-01 2025-07-31 12709586 core:IntangibleAssetsOtherThanGoodwill 2025-07-31 12709586 core:IntangibleAssetsOtherThanGoodwill 2023-08-01 2024-07-31 12709586 core:IntangibleAssetsOtherThanGoodwill 2024-07-31

# IDEAL DIABETES CIC

## Company limited by guarantee

## Company Registration Number:
12709586 (England and Wales)

## Unaudited statutory accounts for the year ended 31 July 2025

## Period of accounts

## Start date: 1 August 2024

## End date: 31 July 2025

# IDEAL DIABETES CIC

## Contents of the Financial Statements

for the Period Ended 31 July 2025

Directors report |
Profit and loss |
Balance sheet |
Additional notes |
Balance sheet notes |
Community Interest Report |

# IDEAL DIABETES CIC

Directors' report period ended 31 July 2025

The directors present their report with the financial statements of the company for the period ended 31 July 2025

Principal activities of the company

The company's principal activity during the period was to improve care pathways for people with diabetes.

Directors

The directors shown below have held office during the whole of the period from
1 August 2024 to 31 July 2025

John Grumitt
Anne Phillips

The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006

This report was approved by the board of directors on
25 March 2026

And signed on behalf of the board by:
Name: John Grumitt
Status: Director

# IDEAL DIABETES CIC

## Profit And Loss Account

for the Period Ended 31 July 2025

| 2025 | 2024
--- | --- | ---
| £ | £
Turnover: | 28,000 | 61,999
Gross profit(or loss): | 28,000 | 61,999
Administrative expenses: | ( 25,715 ) | ( 61,724 )
Operating profit(or loss): | 2,285 | 275
Profit(or loss) before tax: | 2,285 | 275
Tax: | ( 434 ) | ( 52 )
Profit(or loss) for the financial year: | 1,851 | 223

# IDEAL DIABETES CIC

## Balance sheet

As at 31 July 2025

| Notes | 2025 | 2024
--- | --- | --- | ---
|  | £ | £
Current assets
Cash at bank and in hand: |  | 5,714 | 31,452
Total current assets: |  | 5,714 | 31,452
Creditors: amounts falling due within one year: | 3 | ( 1,237 ) | ( 28,826 )
Net current assets (liabilities): |  | 4,477 | 2,626
Total assets less current liabilities: |  | 4,477 | 2,626
Total net assets (liabilities): |  | 4,477 | 2,626
Members' funds
Profit and loss account: |  | 4,477 | 2,626
Total members' funds: |  | 4,477 | 2,626

The notes form part of these financial statements

# IDEAL DIABETES CIC

## Balance sheet statements

For the year ending 31 July 2025 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 3 March 2026
and signed on behalf of the board by:

Name: John Grumitt
Status: Director

The notes form part of these financial statements

# IDEAL DIABETES CIC

## Notes to the Financial Statements

for the Period Ended 31 July 2025

- ## 1. Accounting policies

  Basis of measurement and preparation

  These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

  Turnover policy

  Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.

  Other accounting policies

  Debtors Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts. Creditors Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method. Provisions Provisions (ie liabilities of uncertain timing or amount) are recognised when there is an obligation at the reporting date as a result of a past event, it is probable that economic benefit will be transferred to settle the obligation and the amount of the obligation can be estimated reliably.

# IDEAL DIABETES CIC

## Notes to the Financial Statements

for the Period Ended 31 July 2025

- ## 2. Employees

  | 2025 | 2024
  --- | --- | ---
  Average number of employees during the period | 0 | 0

# IDEAL DIABETES CIC

## Notes to the Financial Statements

for the Period Ended 31 July 2025

## 3. Creditors: amounts falling due within one year note

| 2025 | 2024
--- | --- | ---
| £ | £
Trade creditors | 0 | 82
Taxation and social security | 434 | 24
Other creditors | 803 | 28,720
Total | 1,237 | 28,826

# COMMUNITY INTEREST ANNUAL REPORT

### IDEAL DIABETES CIC

### Company Number: 12709586 (England and Wales)

### Year Ending: 31 July 2025

Company activities and impact

Ideal Diabetes CIC develops, produces and distributes materials to help health professionals and those in receipt of care. It targets unmet needs in order to address gaps and generate impact. By improving understanding and awareness of best in class care, we equip people with the tools to apply the tools required to improve outcomes. Examples include the earlier detection and prevention of foot ulcers. Our ACT NOW! Tools have been endorsed and adopted by professional and patient organisations in the UK and internationally whose members have distributed them to their members through which knowledge, care and patient outcomes are improved. A similar approach has been taken to address a range of elements of care for people with diabetes. In addition, these tools are all freely available to access via our website: www.idealdiabetes.com

Consultation with stakeholders

The company is in regular contact with stakeholders to shape its approach, engagement and development of materials for the benefit of people with diabetes and those in receipt of care. Contact is made via attendance at professional conferences at which presentations are made to build awareness of Ideal Diabetes’s tools for health care professionals. These have Included Diabetes UK’s Annual Professional Congress and Diabetes Professional Care. The directors have also applied themselves to stakeholder engagement as academic and patient advocates, gathering feedback, incorporating this in the development, production and distribution of material it produces.

Directors' remuneration

No remuneration was received

Transfer of assets

No transfer of assets other than for full consideration

This report was approved by the board of directors on
3 March 2026

And signed on behalf of the board by:
Name: John Grumitt
Status: Director